08/10/2025
Another look at Oligodendrocyte Precursor Cell (OPC) transplants for SCI:
The company Lineage Cell Therapeutics has launched another clinical trial involving Oligodendrocyte Precursor Cell (OPC) transplants. RIRC followers will remember that this was the approach pioneered by Hans Keirstead 20 years ago that led to the original Geron trial, which was the first clinical trial of stem cell transplants for SCI funded by the California Institute for Regenerative Medicine. The purpose of this new clinical trial is to evaluate safety and performance of a new injection device. Of note, this trial will enroll participants with both acute and chronic injuries and treatment of an individual with a chronic injury has just been announced (below). Although the purpose of the trial is to evaluate the new injection device, the company will be carrying out functional assessments on all patients, to investigate any signals of efficacy.
The new trial is an exciting opportunity to learn more about surgical techniques for cell delivery into the injured spinal cord and the potential of OPC’s to enhance function.
Lineage Cell Therapeutics has treated the first-ever chronic Spinal Cord Injury patient with OPC1 in its DOSED study at UC San Diego Health.
To read more, use the link below:
https://investor.lineagecell.com/news-releases/news-release-details/lineage-announces-dosing-first-patient-new-clinical-study-opc1
